使用分子对接和动态模拟来识别天然植物化学物质作为AKT2抑制剂,作为潜在的癌症治疗药物
Jibon Kumar Paul1, Mahir Azmal1, Md Naimul Haque Shohan1
1Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet, 3114, Bangladesh.
Heliyon
|February 3, 2025
概括
像米莱顿和乌扎里基宁这样的天然化合物显示出抑制AKT2的潜力,AKT2是癌症进展和治疗耐药性的关键驱动因素. 这些植物化学物质可以为癌症治疗和潜在的神经退行性疾病提供新的途径.
科学领域:
- 生物化学和分子生物学
- 计算化学计算化学
- 药理学 药理学 是一个学科.
背景情况:
- PI3K/AKT/mTOR通路调节关键细胞功能,包括增殖,生存,新陈代谢和血管生成.
- AKT2异型的失调与各种癌症有关,促进瘤的进展,转移和对治疗的抗性.
- 向AKT2为癌症治疗提供了一个重要的治疗策略.
研究的目的:
- 使用计算方法识别能够抑制AKT2异型的天然植物化学物质.
- 评估已识别的植物化学品与AKT2.2的结合亲和力和稳定性.
- 探索这些化合物的潜力,作为AKT2驱动癌症和神经退行性疾病的新疗法.
主要方法:
- 用分子对接模拟来选自然化合物库中的AKT2抑制潜力.
- 进行了分子动力学模拟,以评估顶级抑制剂的稳定性和结合相互作用.
- 使用对接分数量化结合亲和力,并通过基于模拟的分析 (如RMSD和SASA) 进行验证.
主要成果:
- 米莱对AKT2具有最高的结合亲和力 (-9.5 kcal/mol),其次是乌扎里基宁 (-9.0 kcal/mol),二生物素A (-8.9 kcal/mol) 和亚比西I (-8.7 kcal/mol).
- 这些化合物表现优于控制抑制剂伊帕塞尔蒂布 (-7.56 kcal/mol).
- 分子动力学模拟证实了米莱顿,乌扎里根因和二生物素A与AKT2的稳定相互作用,乌扎里根因表现出显著的稳定性.
结论:
- 米莱顿,乌扎里基宁和二生物素A是通过计算查识别的AKT2的强有力的天然抑制剂.
- 乌扎里根因的优越结合稳定性表明它是进一步治疗开发的特别有前途的候选人.
- 这些发现支持这些植物化学物质作为AKT2相关癌症的新疗法剂的潜力,并需要进一步研究神经退行性应用.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K


